pharmaceutical combination comprising nucleotide and nucleoside reverse transcriptase inhibitors (such as tenofovir and lamivudine) in different parts of the dosage unit.

摘要

A pharmaceutical formulation in a single unit dosage, wherein the dosage form comprises: (a) a nucleoside reverse transcriptase inhibitor, and (b) a nucleotide reverse transcriptase inhibitor formulation being in the form of a multilayered tablet or a central coated tablet and wherein the nucleoside reverse transcriptase inhibitor is provided in a different region of the dosage form the nucleotide reverse transcriptase inhibitor.